

In 2020 and 2021 there were considerably lower levels of influenza in the UK, likely due to public health measures utilised to reduce the spread of COVID-19. As we enter a new phase of the pandemic where restrictions have been relaxed, it is possible that cases of influenza will return to pre-pandemic levels and add pressure to the NHS and care systems.

BACKGROUND


- The NIHR has called for a **platform trial to evaluate therapeutic interventions for influenza**.
- We are delighted to announce that REMAP-CAP was selected to be the platform trial to conduct this important research.
- REMAP-CAP will start recruiting Influenza patients from November 1st.

TARGETS

- **Population:**
 - Adults and children admitted to hospital acutely unwell, with confirmed influenza, will be recruited to the trial
 - Inpatients on the ward and in the ICU
- **Interventions**
 - Anti-virals - Oseltamivir, Baloxavir
 - Dexamethasone
 - Immune modulation - Tocilizumab, Baricitinib

REQUIREMENTS

- We are currently open in many ICUs across the UK and are excited to open REMAP-CAP in more wards and also for paediatric patients.
- We suggest adding additional **PIs for the ward team**, a respiratory, ID, acute medicine and/or paediatrician
- We will be submitting Amendment 37 which will need to be approved at your site **ASAP**, once approved by the regulatory bodies.



UPCOMING WEBINAR

- We are currently organising a webinar for the influenza domain.
- More information on this (e.g., date and time) is coming soon!

Thank you to all current REMAP-CAP sites, we are excited to continue this research journey with you. Welcome to all new/prospective REMAP-CAP sites, we look forward to working with you and together we hope our research can find new expedited treatments for influenza.

MORE INFORMATION

On the grant

[22/124 A platform trial to evaluate therapeutic interventions for Influenza specification document](#)

Contact us if you wish to find out more:

ukremap-cap@icnarc.org